DexCom, Inc. (DXCM) Receives $152.25 Consensus Target Price from Analysts

Shares of DexCom, Inc. (NASDAQ:DXCM) have received a consensus recommendation of “Buy” from the twenty ratings firms that are presently covering the firm, MarketBeat.com reports. Five investment analysts have rated the stock with a hold recommendation and fourteen have issued a buy recommendation on the company. The average 12-month price target among analysts that have issued ratings on the stock in the last year is $150.65.

A number of equities research analysts have commented on DXCM shares. Northland Securities restated a “hold” rating and issued a $125.00 target price on shares of DexCom in a research report on Thursday. TheStreet downgraded DexCom from a “c” rating to a “d+” rating in a research report on Friday, April 5th. Raymond James reduced their target price on DexCom from $160.00 to $150.00 and set an “outperform” rating on the stock in a research report on Thursday, May 2nd. Cowen lifted their target price on DexCom from $150.00 to $175.00 and gave the company an “outperform” rating in a research report on Friday, February 22nd. Finally, Zacks Investment Research upgraded DexCom from a “hold” rating to a “buy” rating and set a $138.00 target price on the stock in a research report on Monday, May 6th.

In related news, insider Andrew K. Balo sold 10,917 shares of the business’s stock in a transaction on Tuesday, March 12th. The stock was sold at an average price of $142.79, for a total value of $1,558,838.43. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO Kevin R. Sayer sold 32,566 shares of the business’s stock in a transaction on Tuesday, March 12th. The shares were sold at an average price of $142.83, for a total value of $4,651,401.78. The disclosure for this sale can be found here. Insiders sold a total of 124,189 shares of company stock worth $16,536,917 in the last quarter. Company insiders own 1.80% of the company’s stock.

Several hedge funds have recently bought and sold shares of DXCM. Laurel Wealth Advisors LLC purchased a new stake in DexCom during the 4th quarter worth about $26,000. Harel Insurance Investments & Financial Services Ltd. purchased a new stake in DexCom during the 4th quarter worth about $33,000. Private Ocean LLC purchased a new stake in DexCom during the 1st quarter worth about $36,000. Kore Private Wealth LLC purchased a new stake in DexCom during the 1st quarter worth about $40,000. Finally, Canton Hathaway LLC purchased a new stake in DexCom during the 1st quarter worth about $41,000. Hedge funds and other institutional investors own 96.43% of the company’s stock.

NASDAQ:DXCM traded down $2.77 on Thursday, reaching $120.70. The company’s stock had a trading volume of 1,458,532 shares, compared to its average volume of 1,291,682. DexCom has a 12-month low of $87.69 and a 12-month high of $156.16. The company has a quick ratio of 6.75, a current ratio of 7.18 and a debt-to-equity ratio of 1.57. The company has a market capitalization of $10.99 billion, a P/E ratio of 402.32 and a beta of 0.70.

DexCom (NASDAQ:DXCM) last posted its earnings results on Wednesday, May 1st. The medical device company reported ($0.05) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.17) by $0.12. DexCom had a positive return on equity of 8.45% and a negative net margin of 11.51%. The company had revenue of $280.50 million for the quarter, compared to the consensus estimate of $246.10 million. During the same quarter in the previous year, the business earned ($0.30) earnings per share. The company’s revenue for the quarter was up 52.1% on a year-over-year basis. Sell-side analysts anticipate that DexCom will post 0.81 earnings per share for the current fiscal year.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers. Its products include DexCom G6, a CGM system for diabetes management; DexCom G5 mobile CGM system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system.

Recommended Story: Using the New Google Finance Tool

Analyst Recommendations for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.